Tharsika Manokumar

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background/Purpose: The 85+-year-old population – the " oldest old " – is now the fastest growing age segment in Canada. Although existing research demonstrates high health services utilization and prescribed medications in this population , little epidemiological evidence is available to guide care for this age group. Objective: To describe the(More)
OBJECTIVE Since the benefits of chemotherapy in treating older men with metastatic castration-resistant prostate cancer (mCRPC) are modest, validated tools that predict the risk of treatment toxicity may aid clinical decision-making. Whether these tools are better than oncologist judgment remains unclear. We compared the Cancer and Aging Research Group(More)
BACKGROUND Treatment of metastatic castration-resistant prostate cancer (mCRPC) with chemotherapy improves disease control and survival in fit older men (age 65+) but its impact on function is not clear. We hypothesized that chemotherapy would impair daily function in older men with mCRPC. METHODS Men aged 65+ with mCRPC starting chemotherapy or(More)
  • 1